Media
Corgentech to Present at Credit Suisse First Boston Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Credit Suisse First Boston Annual Healthcare Conference on Thursday, November 18, 2004 at 4:30 p.m. Mountain Standard Time in Phoenix, Arizona.
To access the audio-only live webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investor Calendar page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. The company is creating a pipeline of novel therapeutics based on its proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit www.corgentech.com.
SOURCE Corgentech Inc.
Jennifer Cook Williams of Corgentech, +1-650-624-9600, or [email protected]; or Daryl Messinger of WeissComm Partners, +1-415-999-2361, or [email protected], for Corgentech
http://www.corgentech.com
Copyright (C) 2004 PR Newswire. All rights reserved.
News Provided by COMTEX
